Tracking health data in advanced cancer patients during treatment
Proof of Concept (POC) Prospective Observational Study to Test a Framework for Integration of Data Streams, Including Molecular Genomic Markers and Wearable Device Data in Patients Receiving Chemotherapy for Advanced Cancer
This study is trying to see how different health data from advanced cancer patients receiving treatment can help us understand their physical performance and cancer outcomes better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University College, London Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (London) |
| Trial ID | NCT05971277 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect and analyze biometric, health-related quality of life (HRQoL), immune response, and genomic data from patients with advanced cancer undergoing chemotherapy or immunotherapy. By utilizing a novel platform that integrates various data streams, including electronic medical records and wearable devices, the study seeks to generate complex datasets for machine learning analysis. The primary goal is to explore the relationship between physical performance, genomic profiles, and cancer outcomes, ultimately informing future patient care and research.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with metastatic or hematological cancer who are undergoing systemic therapy and can ambulate independently.
Not a fit: Patients with physical disabilities that prevent daily walking or those unable to provide informed consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of how different health metrics impact cancer treatment outcomes, leading to more personalized patient care.
How similar studies have performed: While the integration of diverse health data streams is a novel approach, similar studies have shown promise in improving patient outcomes through data-driven insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ● A diagnosis of a metastatic or haematological cancer undergoing systemic therapy * Undergoing at least 1 planned cycle of chemotherapy or immunotherapy, according to standard of care practices. * Ability to understand and the willingness to sign a written informed consent. * Able to ambulate without assistance or walking aid. * Have an Android or iOS phone and willing to download the Ethera app Exclusion Criteria: * ● Physical disabilities that preclude daily walking * Inability to provide informed consent. * Unable to use and operate the Ethera Health Monitoring Smartphone App. (Apple or Android) * Medical or psychiatric condition which in the investigator's opinion would affect the successful completion of the study.
Where this trial is running
London
- UCL London — London, United Kingdom (Recruiting)
Study contacts
- Study coordinator: John D Kelly, Professor
- Email: j.d.kelly@ucl.ac.uk
- Phone: 07549152902
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.